PRODUCT INFORMATION

PF-07104091

Item No. 41356

CAS Registry No.:	2460249-19-6
Formal Name:	carbamic acid N-(1-methylethyl)-(1R,3S)-3-[5-[[[3-(methoxymethyl)-1-methyl-1H-pyrazol-5-yl] carbonyl]amino]-1H-pyrazol-3-yl] cyclopentyl ester
Synonym:	Tagtociclib
MF:	$C_{19}H_{28}N_6O_4$
FW:	404.5
Purity:	≥95%
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

PF-07104091 is supplied as a solid. A stock solution may be made by dissolving the PF-07104091 in the solvent of choice, which should be purged with an inert gas. PF-07104091 is sparingly soluble (1-10 mg/ml) in ethanol and DMSO.

Description

PF-07104091 is an inhibitor of cyclin-dependent kinase 2 (Cdk2; K_i = 1.16 nM).[1] It is selective for Cdk2 over glycogen synthase kinase 3β (GSK3β; K_i = 537.81 nM). PF-07104091 decreases proliferation of TOV-21G and OVCAR-3 ovarian and HCT116 colorectal cancer cells (IC_{50}s = 4.8, 0.59, and 0.88 µM, respectively).[2] *In vivo*, PF-07104091 (50 mg/kg per day) reduces tumor volume and weight in an HCT116 mouse xenograft model.

References

1. Behenna, D.C., Freeman-Cook, K.D., Hoffman, R.L., *et al.* CDK2 Inhibitors. *Pfizer, Inc.* **WO 2020/157652 A2** (2020).
2. Liu, Z., Yang, Y., Sun, X., *et al.* Discovery of novel antitumor small-molecule agent with dual action of CDK2/p-RB and MDM2/p53. *Molecules* **29(3)**, 725 (2024).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM